Evidence map›Paper›PMID 40059621›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Antiretroviral Therapy Within 2 Years of HIV Acquisition Is Associated With Fewer Viral Blips: A Retrospective Analysis of More Than 20 Years of Data From the US Military HIV Natural History Study.

Trevor A Crowell, Hsing-Chuan Hsieh, Xun Wang, Xiuping Chu, Britt Gayle, Catherine M Berjohn, Jason M Blaylock, Joseph M Yabes, Derek T Larson, John H Powers and 4 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. New Data and Next Steps for Clarifying How the Timing of Antiretroviral Therapy Initiation Influences Viral Blips and HIV Reservoir Size.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Trevor A CrowellUS Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.ORCID 0000-0001-5947-265X
Hsing-Chuan HsiehGlobal Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Xun WangGlobal Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.ORCID 0009-0004-0330-9473
Xiuping ChuGlobal Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.ORCID 0000-0003-2628-290X
Britt GayleUS Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Catherine M BerjohnDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID 0000-0001-5655-8183
Jason M BlaylockInfectious Disease Service, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.ORCID 0009-0007-4942-5826
Joseph M YabesInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Derek T LarsonInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID 0000-0002-6147-7182
John H PowersClinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Robert J O'ConnellInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID 0000-0001-8901-1432
Anuradha GanesanGlobal Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Brian K AganGlobal Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.ORCID 0000-0002-5114-1669
Infectious Disease Clinical Research Program HIV Working Group

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
DoDHJFNational Institute of Allergy and Infectious DiseasesNational Institutes of Health Clinical CenterNCI NIH HHS 75N91019D00024NCI NIH HHS 75N91019F00130NCI NIH HHS HT9425-24-3-0004NCI NIH HHS W81XWH-18-2-0040NIAID NIH HHS Y01 AI005072NIH HHS HU0001190002NIH HHS Y1-AI-5072the Uniformed Services University of the Health Sciences
6 · The paper itself

Abstract

backgroundViral blips have been associated with larger reservoir size and slower decay. Earlier antiretroviral therapy (ART) initiation may decrease the risk of blips.

methodsWe analyzed participants from the US Military HIV Natural History Study with an estimated human immunodeficiency virus (HIV) seroconversion date, viral suppression ≤400 copies/mL within 1 year after starting ART, and at least 3 HIV RNA measurements after suppression. A blip was defined as HIV RNA 401-1000 copies/mL preceded and followed by HIV RNA ≤400 copies/mL without changing ART. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors potentially associated with the time from viral suppression to first blip.

resultsFrom 1996 through 2022, among 1413 participants on stable suppressive ART, 88 (6.2%) had at least one blip, including 68 (77.3%) with only a single blip. The overall incidence was 1.2 blips per 100 person-years (95% CI: .9-1.4). In multivariable modeling, ART initiation within 24 months of estimated HIV acquisition was independently associated with decreased hazard of viral blips compared with ART initiation after more than 24 months (0-6 months HR: 0.29 and 95% CI: .18-.48; 6-12 months HR: 0.43 and 95% CI: .31-.59; 12-24 months HR: 0.46 and 95% CI: .35-.60).

conclusionsParticipants who initiated ART within 2 years of HIV acquisition had lower hazard of blips, potentially reflecting smaller reservoir size and suggesting reservoir plasticity that extends beyond the acute phase of HIV.

Indexed as

Anti-HIV AgentsHIVHIV InfectionsHIV SeropositivityViral LoadAdultFemaleHumansIncidenceMaleMiddle AgedMilitary PersonnelProportional Hazards ModelsRetrospective StudiesRNA, ViralTime FactorsAnti-HIV AgentsRNA, Viralacquired immunodeficiency syndromeanti-HIV agentsantiretroviral agentsreservoirviremia

Identifiers

PMID40059621
PMCPMC12497960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.